Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
101 EUR | +0.60% | -0.30% | +7.05% |
04-30 | GERRESHEIMER AG : Jefferies reaffirms its Buy rating | ZD |
04-29 | Gerresheimer AG acquired minority stake in RxCap Inc. | CI |
Summary
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company is in debt and has limited leeway for investment
- The firm trades with high earnings multiples: 24.25 times its 2024 earnings per share.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+7.05% | 3.72B | B+ | ||
-3.72% | 186B | C+ | ||
-2.60% | 107B | C | ||
-3.79% | 67.44B | A | ||
+2.66% | 50.03B | B- | ||
+16.39% | 47.81B | B- | ||
+4.71% | 41.03B | B+ | ||
+1.38% | 26.85B | B | ||
+1.52% | 25.82B | A- | ||
-1.17% | 25.01B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- GXI Stock
- Ratings Gerresheimer AG